Blosozumab

Blosozumab Chemische Eigenschaften,Einsatz,Produktion Methoden

• Verwenden

  Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2].

• in vivo

  Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats^[1].
  

  Animal Model:	Sprague-Dawley rats [2]
  Dosage:	1, 10, and 100 mg/kg
  Administration:	Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study)
  Result:	Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg.

• Einzelnachweise

  [1] Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30(2):216-24. DOI:10.1002/jbmr.2351
  [2] Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94. DOI:10.1093/toxsci/kfr318

Blosozumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(20)Suppliers